Viridian Therapeutics, Inc.
VRDN
Updated: 24/09/2026, 01:56:44
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
No summaries found.
- Share price
- $21.43
- Market cap
- $2.43B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Stephen F. Mahoney
- Employees
- 252
- IPO date
- 18/06/2014
- Beta
- 0.964
- Last dividend
- $0.00
- Day range
- $21.20 – $22.18
- 52-week range
- $13.18 – $34.29
- 1-day performance
- -3.12%
- 1-year performance
- 62.59%
- Current drawdown (1Y)
- -37.50%
- CIK
- 0001590750
- CUSIP
- 92790C104
- ISIN
- US92790C1045
- Created
- 07/12/2025, 15:00:49
- Last update
- 24/09/2026, 01:56:44
Track Viridian Therapeutics, Inc. with an AI analyst
See which prediction-market events move VRDN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 10/06/2026, 02:02:19
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
GlobeNewsWire • STOCK • 09/06/2026, 11:00:00
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
GlobeNewsWire • STOCK • 19/05/2026, 15:30:00
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Business Wire • STOCK • 07/05/2026, 01:13:00
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Seeking Alpha • STOCK • 05/05/2026, 19:31:15
Viridian eye disease drug benefits chronic patients in late-stage trial
Reuters • STOCK • 05/05/2026, 09:05:13
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
Seeking Alpha • STOCK • 02/04/2026, 15:12:11
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Zacks Investment Research • STOCK • 01/04/2026, 11:10:26
Viridian Therapeutics shares fall over 30% after trial data disappoints
Proactive Investors • STOCK • 30/03/2026, 14:35:04
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Business Wire • STOCK • 30/03/2026, 09:01:00
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
The Motley Fool • STOCK • 21/03/2026, 19:13:31
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research • STOCK • 26/02/2026, 12:01:58